Idiopathic pulmonary fibrosis: Difference between revisions

No edit summary
Line 26: Line 26:
***~70% have consolidation
***~70% have consolidation


==Diagnostics==
==Differential Diagnosis==
{{Pulmonary fibrosis differential}}
 
==Diagnosis==
*CBC, leukocytosis
*CBC, leukocytosis
*CRP elevated
*CRP elevated
*LDH elevated
*LDH elevated
*ABG with hypoxemia, hypercapnea
*ABG with hypoxemia, hypercapnea
*EKG
*ECG
*CXR with likely need for CT
*CXR with likely need for CT
*Echo to assess for pulm HTN, r/o CHF
*Echo to assess for pulm HTN, r/o CHF
*BAL in ICU to r/o infection
*BAL in ICU to r/o infection
==DDx==
{{Pulmonary fibrosis differential}}


==Management==
==Management==
Line 68: Line 68:
*[[Pulmonary hypertension]]
*[[Pulmonary hypertension]]


==Sources==
==References==
*Bhatti H et al. Approach to acute exacerbation of idiopathic pulmonary fibrosis. Ann Thorac Med. 2013. Vol 8, Issue 2. Pg 71-77.
*Collard HR et al. Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2007 Oct 1; 176(7): 636–643.
*Ryerson CJ et al. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J. 2015 Aug;46(2):512-20.
*Juarez MM et al. Acute exacerbation of idiopathic pulmonary fibrosis—a review of current and novel pharmacotherapies. J Thorac Dis. 2015 Mar; 7(3): 499–519.
<references/>
<references/>
[[Category:Pulmonary]]
[[Category:Pulmonary]]

Revision as of 15:01, 18 May 2016

Background

  • Normal lung parenchyma is interspersed with areas of decrease compliance
    • Unlike ARDS in which lung injury more uniform
    • MV strategies learned from ARDS not completely transferrable
  • Median survival time 3 yrs after diagnosis
  • Prevalence about 10-20 cases per 100,000 people
  • AE-IPF = Acute Exacerbation of IPF
  • Acute exacerbations carry mortality up to 80%
  • 60% die from idiopathic pulmonary fibrosis, others die from:
    • VTE
    • Cardiovascular (ACS, CHF)
    • Infection

Clinical Features

  • Diagnosis of exclusion
  • Presentations with rapid deterioration without obvious cause commen
  • May co-exist with pulmonary HTN and heart failure
  • Diagnostic criteria for acute exacerbation of IPF:
    • Dx of IPF
    • Unexplained worsening of dyspnea within 30 days
    • Hypoxemia deviated from baseline ABG
    • No evidence of pulmonary infection
    • Exclusion of alternative causes (i.e. VTE)
    • CT with b/l ground-glass abnormalities/consolidation on a background reticular/honeycomb pattern c/w interstitial pneumonia[1]
      • 100% have b/l ground-glass opacities
      • ~70% have consolidation

Differential Diagnosis

Pulmonary Fibrosis

Diagnosis

  • CBC, leukocytosis
  • CRP elevated
  • LDH elevated
  • ABG with hypoxemia, hypercapnea
  • ECG
  • CXR with likely need for CT
  • Echo to assess for pulm HTN, r/o CHF
  • BAL in ICU to r/o infection

Management

  • All treatments controversial and of questionable efficacy
  • Methylprednisolon 500-1000 mg qd for 3 days[2][3]
  • Heparin drip
    • Alveolar injury predisposes to prothrombotic state
    • Prevents further vascular injury
  • Cyclosporine A 1-2 mg/kg/day with steroids[4]

Mechanical Ventilation Strategies

  • Current strategies controversial, with some contending MV adds insult to AE-IPF
  • NIV may be use as a temporizing measure
  • Low TVs at 6 cc/kg
  • Permissive hypercapnea may be necessary
  • Maintaining minute ventilations
    • High respiratory rates may be necessary
    • Heavy sedation with possible paralysis with cisatricurium
  • Deviations from ARDS tx strategies
    • Must restrict PEEP given to AE-IPF
    • No place for recruitment maneuver or prone postioning
    • Questionable benefit of APRV (BiVent) and high-frequency oscillation ventilation

Disposition

  • ICU
  • ECMO has been used as a bridge to lung transplant
  • Transfer to transplant center if candidate
    • Lung transplant is the only proven therapy to increase long term survival

See Also

References

  1. Akira M, Kozuka T, Yamamoto S, Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178:372-8.
  2. Rice AJ, Wells AU, Bouros D, Du Bois RM, Hansell DM, Polychronopoulos V, et al. Terminal diffuse alveolar damage in relation to interstitial pneumonias. An autopsy study. Am J Clin Pathol 2003;119:709-14.
  3. Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 2002;166:839-42.
  4. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al. Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest 2007;131:954-63.